Glanbia Plc · EURONEXT:GL9
Glanbia — Glanbia Plc Ord — Q3 2025 Earnings Presentation
10 slides from Glanbia's earnings presentation, Nov 5, 2025
Slide 1: Q3 2025 Interim Management Statement
Q3 2025 Interim Management Statement 5 November 2025 Hugh McGuire Mark Garvey Chief Executive Officer Chief Financial Officer
Slide 2: Important Notice
I M P O R T A N T N O T I C E This presentation contains forward-looking statements. These statements have been made by the Directors in good faith based on the information available to them up to the time of their approval of this presentation. Due to the inherent uncertainties, including both econ
Slide 3: Highlights
HIGHLIGHTS Q3 2025 YTD Q3 2025 Group performance ahead of expectations Double digit volume growth for priority growth brands Optimum Nutrition and Isopure in the third quarter, showing strong sequential improvement Continued volume growth in H&N division across both premix and flavour solutions busi
Slide 4: Performance Nutrition (PN)
PERFORMANCE NUTRITION (PN) Strong third quarter driving improved performance year-to-date Total revenue Q3 YTD1 (2.6%) Volume +0.5% Price (0.5%) 53rd Week (2.4%) Acquisitions / Disposals (0.2%) • LFL2 revenue +2.5% excluding SlimFast and Body & Fit % of PN Revenue 68% 19% • LFL2 revenue -0.9% in Ame
Slide 5: Health & Nutrition (H&N)
H E A LT H & N U T R I T I O N ( H & N ) Continued volume growth momentum Total revenue Q3 YTD1 +11.5% Volume +6.9% Price (0.8%) 53rd Week (2.2%) Acquisitions +7.6% • H&N LFL2 revenue growth of +6.1%, driven by strong volume growth • Volume increase driven by strong growth in EMEA and ASPAC • Pricin
Slide 6: Dairy Nutrition (DN)
D A I RY N U T R I T I O N ( D N ) Strong performance through volume and pricing Total revenue Q3 YTD1 +3.2% Volume +3.5% Price +2.6% 53rd Week (2.9%) • LFL2 revenue growth of 6.1% • Strong dairy markets driving volume and pricing increase • Continued strong demand for protein solutions and bioactiv
Slide 7: Strong Balance Sheet
STRONG BALANCE SHEET DEBT M&A / CAPITAL SHAREHOLDER EXPENDITURE RETURNS Net Debt $718.5m Acquisition of Sweetmix for €197m returned via share $41m buyback programmes2 Total committed facilities of $1.4bn Divestitures of SlimFast and Body & Fit for ~$63m1 €103m returned in dividends FY25 capex expect
Slide 8: 2025 Outlook
2025 OUTLOOK Upgrading PN revenue for FY 2025 and adjusted EPS for FY 2025 expected to be at the upper end of the range Revenue Earnings Capital growth growth allocation PN LFL revenue1 growth of PN EBITDA margin 13-14% OCF conversion 80%+ +3-4% (previously +2-3%) H&N EBITDA margin2 18-19% Capex $80
Slide 9: Delivering Better Nutrition: Positioned for long-term growth
DELIVERING BETTER NUTRITION Positioned for long-term growth 1 Strong volume momentum within Performance Nutrition and continued strong demand within Health & Nutrition 2 Strategic initiatives progressed under Group-wide transformation programme to drive efficiencies and optimise the portfolio 3 Focu
Slide 10: A Performance Driven Purpose Led Global Nutrition Company
A PERFORMANCE DRIVEN PURPOSE L E D G L O B A L N U T R I T I O N C O M PA N Y 10 | Glanbia PLC Q3 2025 IMS Presentation